Stocks To Watch EASTON PHARMACEUTICALS INCORPORATED (OTC: EAPH)
Up 32.59% on Wednesday
Easton Pharmaceuticals (EAPH) is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products. The company’s VDX proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, Viorra, is an over-the-counter aid for the treatment of FSAD. Viorra is a topical, daily-use product containing Generally Regarded as Safe (GRAS) ingredients.
EAPH News:
October 13 - Easton Pharmaceuticals (EAPH) Moves Towards Its Viorra Revenue Projections and Initiatives in Mexico With the Appointment of Dr. Daniel Bagi, MD
Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced the appointment of Daniel Bagi, MD as consultant to spearhead Viorra regulatory, patent and product launch initiatives in Mexico.
Dr. Bagi is the lead contact with BMV Medica S.A. de C.V. (BMV) a regulatory & licensing consultantancy company in Mexico, which has been engaged to begin the process of submitting applications to obtain regulatory approvals for its first product, VIORRA, in that country. Dr. Bagi has developed substantial relationships in Mexico for other products over the last 20+ yrs. In addition, Dr. Bagi understands the local regulatory process and will be working closely with BMV to have Viorra approved for sale. With his astute understanding of the market in Mexico, Dr. Bagi will assist Easton Pharmaceuticals on all aspects of marketing Viorra and other Easton products. Along with his Mexican contacts, Dr. Bagi has nurtured contacts in markets within East Asia, which the company anticipates on eventually utilizing. Aside from his appointment as consultant to Easton Pharmaceuticals, the company has entered into discussions with Dr. Bagi for a director and officer position within the company.
Dr. Bagi and BMV estimate the regulatory process to require six to seven months after filing until a marketing approval is obtained. In parallel with the regulatory filing, Easton Pharmaceuticals, through the efforts and relationships of Dr. Bagi, has begun talks with several large companies with a presence in sales and marketing in the women’s health, sexual arousal disorder and the sexual wellness markets. Easton believes, barring any long financing delays, that these regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of Viorra in Mexico in 2012.
“We are very pleased with the appointment of Dr. Daniel Bagi as a chief consultant who with his many contacts in Mexico, knowledge and belief in our Viorra product, and well established credentials will prove to be a huge asset to the company,” stated John Easton, Easton Pharmaceuticals’ CEO and Chairman of the Board.
Viorra is an over-the-counter aid for the treatment to restore and improve vaginal elasticity and moisture which has shown to give a positive effect on women’s sexual desire and arousal, helping to alleviate FSAD (Female Sexual Arousal Disorder). Viorra is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.
If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.
Please read our Disclaimer regards to EAPH or any company reviewed or blogged about at Strategic Penny Stocks.
